These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Additive-free albumin nanoparticles of alendronate for attenuating inflammation through monocyte inhibition. Markovsky E; Koroukhov N; Golomb G Nanomedicine (Lond); 2007 Aug; 2(4):545-53. PubMed ID: 17716137 [TBL] [Abstract][Full Text] [Related]
8. Biocompatibility of poly(D,L-lactide-co-glycolide) nanoparticles conjugated with alendronate. Cenni E; Granchi D; Avnet S; Fotia C; Salerno M; Micieli D; Sarpietro MG; Pignatello R; Castelli F; Baldini N Biomaterials; 2008 Apr; 29(10):1400-11. PubMed ID: 18191195 [TBL] [Abstract][Full Text] [Related]
9. Development and characterization of hyaluronic acid-anchored PLGA nanoparticulate carriers of doxorubicin. Yadav AK; Mishra P; Mishra AK; Mishra P; Jain S; Agrawal GP Nanomedicine; 2007 Dec; 3(4):246-57. PubMed ID: 18068091 [TBL] [Abstract][Full Text] [Related]
10. Enhanced surface attachment of protein-type targeting ligands to poly(lactide-co-glycolide) nanoparticles using variable expression of polymeric acid functionality. McCarron PA; Marouf WM; Donnelly RF; Scott C J Biomed Mater Res A; 2008 Dec; 87(4):873-84. PubMed ID: 18228271 [TBL] [Abstract][Full Text] [Related]
11. Injectable nanoparticle-loaded hydrogel system for local delivery of sodium alendronate. Posadowska U; Parizek M; Filova E; Wlodarczyk-Biegun M; Kamperman M; Bacakova L; Pamula E Int J Pharm; 2015 May; 485(1-2):31-40. PubMed ID: 25747455 [TBL] [Abstract][Full Text] [Related]
12. Single and double emulsion manufacturing techniques of an amphiphilic drug in PLGA nanoparticles: formulations of mithramycin and bioactivity. Cohen-Sela E; Teitlboim S; Chorny M; Koroukhov N; Danenberg HD; Gao J; Golomb G J Pharm Sci; 2009 Apr; 98(4):1452-62. PubMed ID: 18704956 [TBL] [Abstract][Full Text] [Related]
13. Route of administration-dependent anti-inflammatory effect of liposomal alendronate. Haber E; Afergan E; Epstein H; Gutman D; Koroukhov N; Ben-David M; Schachter M; Golomb G J Control Release; 2010 Dec; 148(2):226-33. PubMed ID: 20813142 [TBL] [Abstract][Full Text] [Related]
14. Fabrication and characterization of PLGA/HAp composite scaffolds for delivery of BMP-2 plasmid DNA. Nie H; Wang CH J Control Release; 2007 Jul; 120(1-2):111-21. PubMed ID: 17512077 [TBL] [Abstract][Full Text] [Related]
15. Influence of microencapsulation method and peptide loading on formulation of poly(lactide-co-glycolide) insulin nanoparticles. Kumar PS; Ramakrishna S; Saini TR; Diwan PV Pharmazie; 2006 Jul; 61(7):613-7. PubMed ID: 16889069 [TBL] [Abstract][Full Text] [Related]
16. Intracellular killing of Brucella melitensis in human macrophages with microsphere-encapsulated gentamicin. Lecároz C; Blanco-Prieto MJ; Burrell MA; Gamazo C J Antimicrob Chemother; 2006 Sep; 58(3):549-56. PubMed ID: 16799160 [TBL] [Abstract][Full Text] [Related]
17. Susceptibility of nanoparticle-encapsulated paclitaxel to P-glycoprotein-mediated drug efflux. Chavanpatil MD; Patil Y; Panyam J Int J Pharm; 2006 Aug; 320(1-2):150-6. PubMed ID: 16713148 [TBL] [Abstract][Full Text] [Related]
18. Novel PDGFbetaR antisense encapsulated in polymeric nanospheres for the treatment of restenosis. Cohen-Sacks H; Najajreh Y; Tchaikovski V; Gao G; Elazer V; Dahan R; Gati I; Kanaan M; Waltenberger J; Golomb G Gene Ther; 2002 Dec; 9(23):1607-16. PubMed ID: 12424613 [TBL] [Abstract][Full Text] [Related]
19. Design of surface-modified poly(D,L-lactide-co-glycolide) nanoparticles for targeted drug delivery to bone. Choi SW; Kim JH J Control Release; 2007 Sep; 122(1):24-30. PubMed ID: 17628158 [TBL] [Abstract][Full Text] [Related]
20. Mucosal or systemic administration of rE2 glycoprotein antigen loaded PLGA microspheres. Brandhonneur N; Loizel C; Chevanne F; Wakeley P; Jestin A; Le Potier MF; Le Corre P Int J Pharm; 2009 May; 373(1-2):16-23. PubMed ID: 19429284 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]